Scholarlink

<p>Identifying ways of averting disabling migraine attacks would be extremely valuable. Long-term preventive therapy is an accepted approach, but even when it is offered, adherence is poor. Prophylactic therapy based on premonitory symptoms (PSs), such as yawning and irritability, that precede migraine in many patients has received little attention, partly because PSs are difficult to define. Recent well-designed studies in calcitonin gene-related peptide pathway antagonists found galcanezumab for 3 months or ubrogepant during PSs reduced headaches in patients with PSs. More studies of migraine PSs are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Minimize morbidity with prophylactic migraine management

  • 期刊论文

  • 发表日期：

    2025年6月24日

查看全文
  • Caroline Fenton,
  • Simon Fung

摘要

Identifying ways of averting disabling migraine attacks would be extremely valuable. Long-term preventive therapy is an accepted approach, but even when it is offered, adherence is poor. Prophylactic therapy based on premonitory symptoms (PSs), such as yawning and irritability, that precede migraine in many patients has received little attention, partly because PSs are difficult to define. Recent well-designed studies in calcitonin gene-related peptide pathway antagonists found galcanezumab for 3 months or ubrogepant during PSs reduced headaches in patients with PSs. More studies of migraine PSs are warranted.